1233490
doi
10.1038/nrc1891
oai:zenodo.org:1233490
Hassan, Raffit
FitzGerald, David J.
Kreitman, Robert J.
Immunotoxin therapy of cancer
Pastan, Ira
info:eu-repo/semantics/openAccess
Creative Commons Zero v1.0 Universal
https://creativecommons.org/publicdomain/zero/1.0/legalcode
Rationally designed anticancer agents that target cell-surface antigens or receptors represent a promising approach for treating cancer patients. However, antibodies that bind these targets are often, by themselves, non-cytotoxic. By attaching potent toxins we can dramatically improve the clinical utility of some anti-tumour antibodies. Here we describe the construction and clinical utility of several recombinant immunotoxins; each of which is composed of antibody Fv fragments fused to powerful bacterial toxins. Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy.
Zenodo
2006-07-01
info:eu-repo/semantics/article
1233489
1579538992.553745
351987
md5:8a8a6b266f43ed436cce8aece9e80d1c
https://zenodo.org/records/1233490/files/article.pdf
public